

## Fasenra (benralizumab)

### Severe Asthma Coverage Criteria:

1. Prescribed by an asthma specialist, allergist or pulmonologist; and,
2. Patient is  $\geq 6$  years of age and has a pre-treatment serum eosinophil count of 150 cells/mcL or greater at screening (within the previous 6 weeks); and,
3. Patient has inadequate asthma control (see criteria #4) despite the following standard therapies:
  - a. Regular use of inhaled steroids (such as Flovent); and,
  - b. Regular use of a long-acting beta-agonist (such as Serevent); and,
  - c. Regular or periodic use of oral steroids; and,
4. Inadequate asthma control despite standard therapies is defined as one of the following:
  - a. At least 2 exacerbations requiring oral systemic corticosteroids in the last 12 months; or,
  - b. At least 1 exacerbation treated in a hospital or requiring mechanical ventilation in the last 12 months; and,
5. Patient is not currently using another biologic therapy for the treatment of asthma such as Cinqair, Dupixent, Nucala or Xolair; and,
6. Patient has tried and failed treatment with Nucala; and,
7. Prescribed within the FDA approved dosing regimen.

### Coverage Duration:

Initial authorizations and reauthorizations will be provided for 12 months

### Renewal Criteria:

1. Patient has been seen by provider in the past 12 months; and,
2. Patient has been adherent to therapy; and,
3. Patient has not experienced unacceptable toxicity; and,
4. Patient has a clinically meaningful response to the medication as defined:
  - a. Decreased frequency of exacerbations defined as:
    - i. Improvement of asthma control, demonstrated by decreased use of oral or systemic corticosteroids; or,
    - ii. Less frequent hospitalizations; or,
    - iii. Reduced frequency of emergency department visits; or,
  - b. Improvement in lung function measured in FEV1; and,
5. Patient is not currently using another biologic therapy for the treatment of asthma such as Cinqair, Dupixent, Fasentra or Xolair; and,
6. Patient has tried and failed treatment with Nucala (members currently treated with Fasentra will be provided 60 days to transition to Nucala); and,
7. Prescribed within FDA approved dosing regimen.